GLP1R and neurodegenerative disease: Clinical studies further indicate that GLP-1R agonists alter neural responses to reward-related cues, influence mood-related outcomes, and are associated with reduced risk of cognitive decline, although results pertaining to benefits in neurodegenerative disease remain mixed.